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Alopecia areata a¡ects approximately 4.6 million indi-
viduals in the United States alone. It is typi¢ed by pat-
chy hair loss on the scalp that can progress to cover the
entire scalp (alopecia totalis) and eventually the entire
body (alopecia universalis). Despite the high incidence
of this condition, its genetic basis is largely unknown.
It is now generally accepted, however, that it ¢ts the
paradigm of a complex trait, in which a combination
of genetic and environmental factors results in the ¢nal
phenotype. Genetic studies have been limited thus far
to association analyses, which suggest that a permissive
HLA status may potentiate the development of alopecia
areata. A systematic screen for identifying the primary
genetic mechanisms underlying this disorder has never
before been undertaken, however. Here we discuss our
approach to the identi¢cation of susceptibility genes
for alopecia areata. In particular, we recently initiated
a comprehensive genetic analysis by performing a gen-
ome-wide scan in a collection of alopecia families with
multiple a¡ected family members. There are currently
a number of examples of complex diseases of the skin,
such as psoriasis and atopic dermatitis, in which genetic
studies are being undertaken that substantiate the time-
liness of this approach. We anticipate that these studies
will lead to the identi¢cation of the susceptibility genes
and provide a foundation for understanding how they
interact with each other and with other variables,
such as the immune system and environmental factors.
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A
lopecia areata (AA) is typi¢ed by patchy hair loss on
the scalp that can progress to cover the entire scalp
(alopecia totalis, AT), and eventually the entire body
(alopecia universalis, AU). AA a¡ects approximately
4.6 million individuals in the United States alone,
including males and females of all ages and ethnic groups (Price,
1991; Sawaya and Hordinsky, 1992; Schwartz and Janniger, 1997;
Madani and Shapiro, 2000). Despite this high incidence, the
pathomechanisms underlying AA are largely unknown. An auto-
immune etiology has been suggested for many years, but an
autoantigen has never been identi¢ed. It is now generally ac-
cepted that AA ¢ts the paradigm of a complex or multifactorial
trait, in which genetic and environmental factors combine to re-
sult in the ¢nal phenotype (Green and Sinclair, 2000; McElwee
et al, 2001; McDonagh and Tazi-Ahnini, 2002; McElwee and
Ho¡mann, 2002). So far, genetic studies have been restricted to
association analyses, which suggest that a permissive HLA status
may potentiate the development of AA. However, a systematic
screen for identifying the primary genetic mechanisms underly-
ing this disorder has never been undertaken.
Discovery of genes directly implicated in the pathogenesis of
AA would have far-reaching implications for basic science and,
importantly, for a¡ected individuals. The pathology of AA
extends far beyond the physical aspects of hair loss and can have
a deeply disturbing psychological impact. This impact embraces
not only hair loss but the quality of life, the ability to function
in society, and the preservation of self-esteem as well. There are
few diseases as prevalent as AA in which a complete lack of under-
standing precludes prediction of disease course or even develop-
ment of a widely e¡ective treatment.With the completion of the
Human Genome Project, we are now well positioned to begin a
comprehensive genetic analysis of AA. Here we describe our
approacha genome-wide scan in a large cohort of AA families
with multiple a¡ected family members that will systematically
pinpoint candidate susceptibility genes for AA and potentially
illuminate therapeutic targets for AA patients in the future.
ALOPECIA AREATA:THE DISEASE
It is estimated that AA a¡ects between 2% and 4% of patients
within average dermatology practices (Price, 1991). It usually be-
gins as one or several oval patches of nonscarring hair loss in the
scalp that can appear suddenly or more gradually over several
days or weeks. The hair loss may regress, or the patches can coa-
lesce and progress to cover the entire scalp (AT) and eventually
the entire body (AU). AA is sometimes accompanied by nail
changes in the form of pitting, brittleness, and splitting. In all,
the prognosis of AA is unpredictable and there is no de¢nitive
treatment.
The pathogenetic basis and etiology of AA are largely un-
known. In the initial stages, the number of hair follicles appears
to remain the same; however, in the more advanced stages this
number decreases and miniaturization of the anagen hair follicles
is observed (McDonagh and Messenger, 1996). A cardinal feature
of AA is the presence of a lymphocytic in¢ltrate in the scalp
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biopsies of a¡ected patients. This, together with the response of
patients to steroid treatment, has led to the suggestion of an auto-
immune mechanism (Khoury et al, 1988;Welsh et al, 1994). It was
recently hypothesized that melanocyte-associated antigens could
induce hair loss in AA (Gilhar et al, 2001). However, an autoanti-
gen has never been identi¢ed. On the other hand, haplotype as-
sociation studies suggest that a permissive HLA status may
potentiate the development of the AA phenotype (Kianto et al,
1977; Kuntz et al, 1977; Hacham-Zadeh et al, 1981; Morling
et al, 1991;Welsh et al, 1994; Colombe et al, 1995; de Andrade et al,
1999). Although studies describing a positive association between
HLA and AA are numerous, there is a lack of biological data im-
plicating speci¢c alleles in the disease phenotype. Moreover, asso-
ciation between HLA and AA has been excluded in some familial
cases of this disease (Zlotogorski et al, 1990).
ALOPECIA AREATA: A COMPLEX TRAIT
The term ‘‘complex trait’’ is used to describe those phenotypes
that do not exhibit classic Mendelian inheritance attributable to
a single gene locus but that does have a genetic component, as
demonstrated by twin, adoption, and epidemiological studies
(Lander and Schork, 1994).
Polygenic inheritance of alopecia areata No single resource
of evidence for polygenic inheritance exists for AA, although
it is becoming increasingly evident that a signi¢cant genetic
predisposition underlies the AA phenotype (Green and Sinclair,
2000; McElwee et al, 2001; McDonagh and Tazi-Ahnini, 2002;
McElwee and Ho¡mann, 2002). There are several independent
lines of evidence in favor of polygenic inheritance (Aita and
Christiano, 2001), among them (i) the high prevalence of the
trait, typical of complex traits for which the predisposing alleles
are more common than the relatively rare mutations identi¢ed
for Mendelian disorders; (ii) the Gaussian curve of distribution
for both the stages of disease progression and the distribution of
the disease, with a threshold e¡ect that could be lowered by,
for example, the presence of a particular HLA haplotype
or autoimmune susceptibility (Welsh et al, 1994); (iii) the
heritability as de¢ned by both the frequency of a¡ected family
members, ranging from 3% to 42% (Green and Sinclair, 2000),
and concordance in twins (Jackow et al, 1998); and (iv) the
presence of congenital AA, strongly suggesting the contribution
of genetic factors (de Viragh et al, 1997; Bardazzi et al, 1999;
Bereket et al, 2001; Crowder et al, 2002). In addition, Sundberg
and coworkers (Sundberg, this issue) reported the identi¢cation
of potential susceptibility loci underlying the AA phenotype in
the C3H/HeJ mouse model.
Association studies in alopecia areata In a ¢rst attempt to
identify the genetic basis of AA, a number of association studies
for candidate genes have been conducted. Numerous reports
indicate a signi¢cant association between AA and the HLA
alleles DQB10301 (for severe AA) and DRB11104 (Morling
et al, 1991; Welsh et al, 1994). In a family-based study, DQB103
alleles were shown to be present in 85% of AA patients as
compared to 46% of controls (de Andrade et al, 1999). Several
authors have also suggested association with the IL-1 receptor
antagonist gene (IL-1RN) and the IL-1 receptor antagonist
homolog IL-1L1 (Tarlow et al, 1994; Barahamani et al, 2002; Tazi-
Ahnini et al, 2002), as well as with the MX1gene on chromosome
21 (Tazi-Ahnini et al, 2000). Finally, a strong association between
autoimmune polyglandular syndrome type 1 (APS1), caused by
mutations in the AIRE gene on chromosome 21, and AA has
also been reported (Betterle et al, 1998). In their study, Betterle
and colleagues observed AA in 37% of their APS1 patients.
Linkage analysis in complex traits A genome-wide scan on
large cohorts of patients has been previously performed with
success for the study of complex traits. For example, a number
of groups have performed genome-wide scans in families
a¡ected with psoriasis and have identi¢ed at least three
predisposing genetic loci on chromosomes 4, 6, and 17 (Bhalerao
and Bowcock, 1998). Atopic dermatitis, another complex skin
disease, has also been the subject of genetic studies (Lee et al,
2000; S˛derhll et al, 2001; Bradley et al, 2002). Lee and
colleagues reported the identi¢cation of a major susceptibility
locus on chromosome 3 (Lee et al, 2000). It is anticipated that
this type of study will lead to the identi¢cation of the
pathomechanisms for these common diseases, as has been the
case for Crohn’s disease, with the identi¢cation of the actual
alleles conferring susceptibility in the NOD2 gene (Hugot et al,
2001; Ogura et al, 2001).
IDENTIFYING SUSCEPTIBILITY GENES FOR ALOPECIA
AREATA:THE GENOME-WIDE SCAN
As discussed above, the genome-wide linkage strategy has been
previously applied to the study of complex traits. The design of
a complex trait study is dependent on three variables: (i) the col-
lection of families; (ii) the number and spacing of genetic mar-
kers; and (iii) the statistical power to identify a locus as a
function of these choices. These three considerations of the study
design are addressed in the following sections.
Diagnostic criteria and ascertainment of alopecia areata
families Critical to the success of any genome-wide initiative
for a complex disease is a patient collection that ful¢lls a
number of requirements: (i) accurate and uniform diagnosis; (ii)
a large size for the results to be signi¢cant; (iii) a sample in which
the contribution of genetic factors is enriched; and (iv) a sample
amenable to analysis as a single group or as smaller, more
homogeneous subgroups.
Although AA presents with some cardinal morphological and
histological features, its diagnosis can be complicated by the
variability in hair loss and the characteristic waxing and waning
nature of the disease. To achieve homogeneity in the collection of
patients, ascertainment, diagnosis, and collection of the families
in our study are being undertaken by dermatologists with long-
standing expertise in AA using the diagnostic questionnaire
developed by the NIH AA Registry. The sources of the AA
families recruited for this study comprise a large group of
families from the Israeli Registry ascertained and diagnosed
personally by A.Z., families from the NIH AA Registry, and
families referred by physicians throughout the United States.
An example of the patient collection used in our study is
shown in Fig 1 and summarized in Table 1, showing a family
history in 35% of the patients examined. The genetic dissection
of complex traits has traditionally been focused on large
collections of small families (a¡ected sib pairs, for example). It
was recently shown, however, that a small sample of larger
pedigrees can potentially derive better results (Tomfohrde et al,
1994; Hugot et al, 1996; Matthews et al, 1996). The rationale for
this is the following: (i) the use of a small sample reduces the
level of genetic heterogeneity (‘‘noise’’) among the pedigrees,
one of the hallmarks of complex traits; (ii) a major contribution
of genetic factors is suspected in pedigrees with several a¡ec-
ted family members (i.e., such families are ‘‘enriched’’ for
predisposing alleles); and (iii) knowing the relationship between
the individuals in a large pedigree results in higher statistical
power (Terwilliger and Goring, 2000). In order to maximize the
success of our study, we have focused our initial e¡orts of
the genome-wide scan in pedigrees with three or more a¡ec-
ted family members. Importantly, such a collection of families is
amenable to the establishment of di¡erent subsets, based on
severity of the disease (patchy AA, AT, or AU) or ethnic origin,
among other criteria.
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Genetic markers In order to achieve statistically signi¢cant
results, a su⁄cient number of highly polymorphic markers must
be genotyped. There are some reports on successful results with a
low number of markers, such as the identi¢cation of the PSOR1
and IBD1 loci conferring susceptibility to psoriasis and Crohn’s
disease, respectively (Matthews et al, 1996; Trembath et al, 1997;
Hugot et al, 2001). In our study, however, we have chosen to
perform a genome-wide scan using a panel of 324 microsatellite
markers, with an average marker spacing of 10 cM and a
semiautomated £uorescence-based genotyping system. Most of
the markers are chosen from version 8.0 of the Marsh¢eld
£uorescence-labeled genome-screening set. This approach has
been described in detail elsewhere (Aita et al, 1999; Liu et al,
2001; Liu et al, 2002) and utilized by our group in collaboration
with the Columbia University Genome Center (Ahmad et al,
1998a; Ahmad et al, 1998b; Martinez-Mir et al, 2002).
Statistical analysis Because of the inherent nature of complex
traits, it is expected that a number of genetic components will
contribute to the ¢nal presentation of the phenotype. However,
di¡erent combinations of genetic factors can contribute to the
disease in each family. For this reason, once the data-set from
the genome-wide scan is obtained, it is extremely critical to
perform a thorough and exhaustive statistical analysis to extract
all possible information. This data-set is amenable to analysis
with a large number and wide variety of statistical tests.
As a ¢rst approach, we will apply the following test statistics
to the data-set obtained in the genome-wide scan: (i) the
heterogeneity LOD score (Smith, 1963; Ott, 1999), maximized
over four settings of the penetrance parameters (MAXHLOD);
and (ii) the mean test for a¡ected sib pairs, as implemented
in the ANALYZE program (Terwilliger and Ott, 1994) (ASP),
a test of allele sharing that uses all sibs (Terwilliger and Ott,
1994) (ALLSIBS) and a likelihood version of the transmission
disequilibrium test (Spielman et al, 1993) as developed by
Terwilliger (Terwilliger, 1995) (TDT-LIKE).
With the MAXHLOD calculations, we will apply a model-
based linkage analysis in which the LOD score is calculated
under both autosomal dominant and autosomal recessive
patterns of inheritance. For both models, two di¡erent values of
penetrance will be considered: 50% and 80%. ASP, ALLSIBS,
and TDT-LIKE tests have been chosen because they are all
genetic model^free (Elston, 1989; Hodge and Elston, 1994) in
the sense that they do not require a speci¢cation of the genetic
model parameters (penetrance and disease allele frequency).
MAXHLOD has been chosen because it has been shown that it
is at least as powerful in localizing disease loci as are tests like
ASP and ALLSIBS (Abreu et al, 1999), and under certain
circumstances it is a more precise indicator of the location of
a disease locus than are statistics like ASP and ALLSIBS (Finch
et al, 2001). Finally, TDT-LIKE will be chosen because it has
been shown that it may be more powerful than linkage tests
(MAXHLOD, ASP, ALLSIBS) when there is linkage and
linkage disequilibrium between a disease and a marker locus.
Some of the AA families collected by A.Z. in Israel are
Ashkenazi Jewish (AJ). The AJ population is considered
genetically isolated, and the extent of linkage disequilibrium is
thought to extend over larger regions of the human genome
(Ostrer, 2001). The strategy to be used here is similar to
exploratory methods employed by other researchers analyzing
genome scan data for complex traits (Wise and Lewis, 1999;Wise
et al, 1999), with the exception that we will study a whole
chromosome at a time rather than subdivide each chromosome
into bins. We consider the whole chromosome as the unit of
measure because in simulated data-sets it has been observed
that the methods we plan to employ are more powerful at
determining the correct chromosome rather than a particular
region of a chromosome harboring a disease susceptibility locus
(Gordon et al, 2001).
Identi¢cation of genes and DNAvariants conferring genetic
susceptibility for alopecia areata Once a complex trait has
been mapped to one or several susceptibility loci, the task of
identifying the speci¢c alleles conferring susceptibility for the
phenotype of interest still remains. First, a small interval of
amenable size for positional cloning is rarely identi¢ed in initial
linkage studies. Second, the nature of a complex disease implies
that the alleles predisposing to the ¢nal phenotype can be
numerous. Finally, DNA variants also present in the general
population, rather than disease-restricted mutations, are the
expected gene variants contributing to the etiology of complex
traits. For this reason, multiple approaches will be utilized in the
identi¢cation of candidate susceptibility genes and alleles for AA.
Fine mapping of susceptibility loci for alopecia areata The
results from the ¢rst stage of the genome-wide scan, as described
above, are expected to indicate the most likely location for the
AA susceptibility genes. In order to con¢rm the results from
this ¢rst stage, as well as to exclude false positive results, a
second stage of analysis will be performed. A dense map of
Figure 1. Representative example of AA pedigrees available for this
study.
Table1. Summary of AA patients examined
Number of a¡ected
family members Number of cases
1 (no family history) 91
2 28
3 10
4 5
5 3
6 1
7 1
13 1
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polymorphic markers in the regions of interest will be developed
using both microsatellite markers and SNPs. These are available
in public databases: UCSC, NCBI, Ensembl, and deCODE
Genetics (Kong et al, 2002) for map and sequence information
on microsatellites and SNPs; the Marsh¢eld genetic map
(Broman et al, 1998) for map information on microsatellites; and
the SNP consortium database (Sachidanandam et al, 2001) for
SNP selection. The entire collection of AA families, together
with newly collected pedigrees, can then be genotyped. If SNP
analysis is required for a large genomic region, and in order to
optimize the genotyping e¡ort in this re¢nement stage, the
presence of haplotype blocks can be determined (Daly et al,
2001; Gabriel et al, 2002). The use of haplotype blocks can
considerably reduce the cost of genotyping, because a few SNPs
are typed that represent the entire haplotype. Statistical analyses
similar to those described above can be applied to exclude
regions in the genome that could represent false positives and to
map the actual susceptibility loci for AA.
Identi¢cation of candidate genes Once the candidate regions
cannot be further re¢ned, it will be necessary to proceed with the
analysis of the genes therein by both in silico and experimental
procedures.We now have access to continuous updated sequence
data of the human genome at three main public databases:
UCSC, NCBI, and Ensembl. Based on the information available
from these databases, a detailed physical map of the region of
interest will be built in order to prioritize the candidate genes to
be analyzed. This usually includes previously known genes, novel
genes, ESTs, and predicted genes. As a second but parallel
approach in the case of AA, we can cross-reference the
positional data from the genome-wide scan with expression
data. Carroll and coworkers have performed expression studies
in human AA patients and in a mouse model for AA (Carroll
et al, 2002). They have distinguished two groups of di¡erentially
expressed genes for the initial and late stages of disease
development. Finally, several animal models for AA have been
described. Among them, the C3H/HeJ mouse and the DEBR
rat have been extensively characterized (McElwee and
Ho¡mann, 2002). Sundberg and coworkers (Sundberg, this
issue) have reported the ¢rst attempt at identifying genes
underlying the AA phenotype in the C3H/HeJ mouse model,
with the identi¢cation of suggestive loci on chromosomes 9 and
17. The study of the syntenic regions containing AA loci in mice
and humans will help in de¢ning candidate genes.
Gene characterization and detection of DNAvariants Once
a candidate gene is identi¢ed, the ¢nal goal will be the
characterization of the actual alleles conferring susceptibility to
the phenotype of interest.With this aim, the candidate gene will
be sequenced in a collection of patients and control individuals.
Because genomic DNA is the material used in a genome-wide
scan, it is necessary to know the genomic structure of the
candidate gene for PCR primer design. The strategy followed
will depend on the available information on each gene. For those
genes fully sequenced as part of the Human Genome Project,
the intron/exon boundaries are known or can otherwise be
determined by cDNA and genomic sequence comparison. For
those genes partially sequenced, a PCR-based cloning strategy
can be followed. Finally, in the case of predicted genes the
predicted gene structure must be veri¢ed by RT-PCR.
For each candidate gene, intron/exon boundaries will
eventually be identi¢ed, as well as £anking intron sequences
for the design of exon-speci¢c PCR ampli¢cation primers for
the detection of DNA variants. For each gene, both coding
and noncoding regionsmainly the promoter regioncan then
be analyzed. The ¢rst samples to be sequenced will usually
be those corresponding to the pedigrees linked to a particular
chromosomal region. Once DNA variants are identi¢ed, both
in coding and noncoding sequences, it will be necessary to test
whether they are signi¢cantly associated with the disease
phenotype. With this goal, their frequency can be determined
in the complete collection of AA families, isolated AA cases, and
a control-matched population. If needed, the cohort of AA
pedigrees can be further subdivided according to severity and
ethnic origin to test for associations between the variants
identi¢ed and particular subgroups of the patient collection.
We anticipate that this type of study will provide a founda-
tion for understanding the interactions of these genes with
each other and with other variables such as the immune system
and environmental triggers. Ultimately, it is expected that this
study will help to de¢ne therapeutic targets for the future and
eventually provide an e¡ective treatment for this psychologically
devastating dermatologic disorder.
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